ERBB2 and cancer: As expected, we identified a lower proportion of ERBB2-high tumors in each cancer type as compared to standard IHC/ISH definition of HER2-positivity, thus potentially selecting tumors sensitive to T-DM1 treatment even in cancer types generally not considered amenable to treatment with this agent.